BiotechTube

ONO-5920

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Involutional Osteoporosis

Conditions

Involutional Osteoporosis

Trial Timeline

May 1, 2003 → —

NCT ID
NCT00212719

About ONO-5920

ONO-5920 is a phase 3 stage product being developed by Ono Pharmaceutical for Involutional Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00212719. Target conditions include Involutional Osteoporosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00212719Phase 3Completed

Competing Products

2 competing products in Involutional Osteoporosis

See all competitors
ProductCompanyStageHype Score
ONO-5920Astellas PharmaPhase 3
77
Minodronic acid hydrateAstellas PharmaPhase 3
77

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77